19 May 2013
Keywords: belinostat, enters, ph, i/ii, trial, copenhagen, denmark-based
Article | 03 September 2007
Copenhagen, Denmark-based TopoTarget AS and US firm CuraGen have
initiated patient dosing in a Phase I/II trial evaluating belinostat
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
17 May 2013
© 2013 thepharmaletter.com